Introduction
============

*Achromobacter* is a ubiquitous, non-fermenting, gram-negative bacterium that lives in soil and aquatic environments. In recent years, many studies have shown that this opportunistic pathogen can lead to various infections, such as sepsis, bacteremia, urinary infection, endocarditis, and peritonitis, especially in immunocompromised individuals ([@B1]). Moreover, this organism can colonize various medical devices, such as disinfectant-soaked unwoven cleaning cloth ([@B21]), intravascular pressure transducer ([@B14]), and chlorhexidine ([@B38]).

To distinguish different *Achromobacte*r strains, various methods have been applied. Similar to OXA-50-like enzymes from *P. aeruginosa* or OXA-51/69 from *A. baumannii*, the *bla~OXA-*114*-like~* gene is a known characteristic of *Achromobacter* ([@B9]; [@B37]). Additionally, multilocus sequence typing (MLST) is one of the best methods for use in epidemiological studies in the world. There are more than 300 STs in the MLST database distributed across the world. However, due to the low incidence of *Achromobacter* infections, no clone complex has been reported.

Elderly patients often have underlying diseases and frequently suffer from chronic infections, which may result in continuous exposure to various types of antibiotics. This exposure may contribute to antibiotic resistance. Based on previous studies, integrons and the inborn RND-Type Multidrug Eﬄux Pump ([@B4]) are the main reasons for antibiotic resistance. Various integrons (intI/intII) have been detected ([@B35]). Additionally, extended-Spectrum β-Lactamases (ESBL) and metallo-b-lactamase (MBL) production by *Achromobacter* spp. has been detected in the last decade. In Europe, *bla~V\ EB~* and *bla~TMB~* inserted in integrons were found in *Achromobacter* spp. ([@B20]; [@B12]). Various subtypes of *bla~VIM~* have been detected in integron I in Asia and Europe ([@B26]; [@B28]; [@B29]). Infections, pandemic or sporadic, are often related to the location of resistance genes (chromosome/plasmid). Thus, the insertion of a new *bla~IMP~*-type gene in plasmids in *A. xylosoxidans* has attracted wide attention because it may spread easily ([@B40]). Moreover, the inherent *bla~OXA-*114*-like~* genes may result in a higher level of OXA-114-mediated-lactam resistance because of the insertion sequence elements ([@B9]). Therefore, *Achromobacter* spp. is an emerging pathogen and is becoming a reservoir for horizontal genetic transfer elements involved in spreading antibiotic resistance ([@B35]).

Hospital-acquired pneumonia (HAP) due to *Achromobacter* spp. has emerged as a substantial concern in recent years. Pulmonary involvement has been frequently reported in cases with underlying disease, especially in cystic fibrosis (CF) ([@B10]; [@B13]). In CF patients, *A. xylosoxidans* isolated from sputum increased gradually ([@B43]; [@B17]). However, CF is a rare disease in China. In non-CF patients, several cases of pneumonia have been reported in patients with underlying malignancy ([@B1]), those with IgM deficiency ([@B11]) and those on mechanical ventilation ([@B6]). Additionally, approximately half of these non-CF patients originated from the community, which may be related to the soil and aquatic environments ([@B31]). However, HAP due to *Achromobacter* spp. in the elderly is rare.

The features of this organism in the elderly need to be urgently studied. Therefore, this study aimed to understand the clinical characteristics, epidemiology, biofilm production and integrons of *Achromobacter* spp. in elderly patients with HAP.

Materials and Methods {#s1}
=====================

Patients
--------

Fifteen patients with HAP due to *Achromobacter* spp. treated in a geriatric ward in China from September 2008 to May 2012 were enrolled in this study. The diagnostic criteria of HAP were as described previously ([@B27]). Patient demographics and clinical characteristics (underlying disease, invasive manipulation, therapy, and mortality) were collected. The Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) score and Clinical Pulmonary Infection Score (CPIS) were evaluated within the first 24 h. Chronic infection was defined as a positive sputum culture on at least three occasions over a 6-month period, as previously suggested ([@B36]).

Microbial Identification and *bla~OXA-*114*-like~* Analysis
-----------------------------------------------------------

*Achromobacter* spp. was cultured from sputum or aspirations more than twice and was the dominant species in the culture. All the strains were identified by the API 20 NE system and the Vitek II system as described previously ([@B22]; [@B34]). Species identification was confirmed by 16S ribosomal RNA gene sequencing ([@B19]). To further classify this organism, a specific PCR based on the detection of *bla~OXA-*114*-like~* was performed ([@B37]).

Multilocus Sequence Typing
--------------------------

The primers and reaction conditions of seven housekeeping genes (*nusA*, *rpoB*, *eno*, *gltB*, *lepA*, *nuoL*, *nrdA*) were designed by searching Pubmlst^[1](#fn01){ref-type="fn"}^. Allelic profiling and ST determination were also performed through the above website. Additionally, phylogenetic analysis of housekeeping genes and eBURST analysis were performed. The concatenation of the seven housekeeping genes (total of 2249 bp) of *Achromobacter* spp. was performed. A dendrogram was constructed from the concatenated sequences by the neighbor-joining method (MEGA 6.05). The eBURST analysis was conducted using eBURST V3.

Biofilm Production Assay
------------------------

All isolates were individually cultured overnight in M-H medium (OXOID). A monoclonal sample from the M-H medium was mixed with LB medium to prepare a bacterial suspension of 0.5 units. Bacterial suspensions (200 μl) were inoculated in a 96-well plate followed by 48 h of incubation at 37°C in a bacterial incubator (German He Liman). Plankton bacteria were removed by washing three times with distilled water every 30 s. The wells were dyed at room temperature for 5 min and then incubated with 200 μl of 1% Crystal Violet dye for 20 min. They were then washed twice with distilled water and dried at 37°C for 30 min. Two hundred microliters of 95% ethanol was added into each well, and the optical density (OD) at 570 nm was measured in a microtiter auto reader (Thermo Fisher Scientific, US) ([@B36]; [@B44]). ATCC *Escherichia coli* DH5a (Ac) was used as a negative control. The established criteria (four levels of biofilm-forming ability) were the following: (1) N: no biofilm producer (-), A ≤ Ac; (2) W: weakly positive (++), Ac \< A ≤ 2Ac; (3) M: moderately positive (++), 2Ac \< A ≤ 4Ac; and (4) S: strongly positive (+++), A \> 4Ac ([@B30]).

Susceptibility Testing
----------------------

Antimicrobial susceptibility testing was conducted using the microbroth dilution method as described previously ([@B40]). The etest was employed for polymyxin B in M-H medium (OXOID) (**Table [1](#T1){ref-type="table"}**). The results were interpreted using the 2015 Clinical and Laboratory Standards Institute (CLSI) guidelines.

###### 

The microbes feature of 15 cases.

  NO.   AN     GM     TOB    ATM    CAZ    FEP    CTX    CRO    CPZ    LEV   CIP   IPM     MEM     TCY    PB   PIP    TZP     SXT      F       Int.   VR                               *bla~OXA-*114*~*    ST    BF
  ----- ------ ------ ------ ------ ------ ------ ------ ------ ------ ----- ----- ------- ------- ------ ---- ------ ------- -------- ------- ------ -------------------------------- ------------------- ----- ----
  1     \>64   \>16   \>16   \>64   4      \>64   \>64   \>64   8      4     4     16      4       8      4    \<16   4/2     \<2/38   \>512   I      *aadB + aadA2*                   *bla~OXA-*114q*~*   307   W
  2     \>64   \>16   \>16   \>64   \>32   \>64   \>64   \>64   32     2     2     2       1       2      1    \<16   4/4     \>4/76   256     I      *dfrA17 + aacA4*                 *bla~OXA-*114q*~*   306   M
  3     \>64   \>16   \>16   \>64   4      32     \>64   \>64   4      1     0.5   4       2       8      1    \<16   4/2     \<2/38   \>512   I      *aadB + aadA2*                   *bla~OXA-*114h*~*   5     W
  4     \>64   \>16   \>16   \>64   16     \>64   \>64   \>64   32     2     \>4   8       0.5     \>16   2    \<16   4/4     \<2/38   \>512   I      *aadB + aadA2*                   *bla~OXA-*114q*~*   306   W
  5     \>64   \>16   \>16   \>64   \>32   \>64   \>64   \>64   \>64   \>8   \>4   4       8       \>16   4    \<16   4/4     \>4/76   256     I      *aadB*                           *bla~OXA-*114h*~*   5     M
  6     \>64   \>16   \>16   \>64   4      \>64   \>64   \>64   4      4     \>4   2       2       8      2    \<16   4/2     \<2/38   \>512   I      *aadB*                           *bla~OXA-*114r*~*   311   W
  7     \>64   \>16   \>16   \>64   8      \>64   \>64   \>64   8      4     4     16      4       8      1    \<16   4/4     \<2/38   \>512   I      *aadB + aadA2*                   *bla~OXA-*114q*~*   312   W
  8     \>64   \>16   \>16   \>64   16     \>64   \>64   \>64   32     4     \>4   64      \>128   \>16   8    64     64/4    \<2/38   256     I      *aadB + aadA2*                   *bla~OXA-*114r*~*   313   S
  9     \>64   \>16   \>16   \>64   8      \>64   \>64   \>64   32     4     2     8       8       8      2    128    128/4   \<2/38   \>512   I      *aadB + aadA2*                   *bla~OXA-*114h*~*   5     M
  10    \>64   \>16   \>16   \>64   16     \>64   \>64   \>64   32     4     \>4   \>128   \>128   \>16   16   32     32/4    \<2/38   \>512   I      *aadB + aadA2*                   *bla~OXA-*114t*~*   314   S
  11    \>64   \>16   \>16   \>64   \>32   32     \>64   \>64   8      \>8   \>4   64      64      2      32   \<16   4/2     \>4/76   \>512   I      *aadB + aadA2*                   *bla~OXA-*114q*~*   306   S
  12    \>64   \>16   \>16   \>64   8      \>64   \>64   \>64   \>64   2     2     16      4       8      2    \<16   4/4     \<2/38   256     I      *aadB + aadA2*                   *bla~OXA-*114q*~*   306   M
  13    \>64   \>16   \>16   \>64   8      \>64   \>64   \>64   4      8     \>4   4       4       \>16   2    \<16   4/4     \<2/38   \>512   I      *aadB + aadA2*                   *bla~OXA-*114q*~*   5     S
  14    \>64   \>16   \>16   \>64   8      \>64   \>64   \>64   64     8     4     4       4       4      8    128    128/4   \<2/38   \>512   I      *blaPSE-1 + aac(6′)-II + aadB*   *bla~OXA-*114q*~*   306   M
  15    \>64   \>16   \>16   \>64   \>32   \>64   \>64   \>64   \>64   8     4     \>128   \>128   \>16   2    \<16   8/4     \<2/38   \>512   I      *aadB + aadA2*                   *bla~OXA-*114r*~*   313   M

AN, amikacin; GM, gentamicin; ATM, aztreonam; CAZ, ceftazidime; FEP, cefepime; CTX, cefotaxime; CRO, ceftriaxone; CPZ, cefoperazone; LEV, levofloxacin; CIP, ciprofloxacin; IPM, imipenem; MEM, meropenem; TCY, tetracycline; PB, polymyxin B; PIP, piperacillin; TZP, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole; F, nitrofurantoin; VR, variable region; ST, sequence typing; BF, bacterial biofilm.

### *Bla~OXA-*114*-like~* Analyses

The dendrogram analysis of *bla~OXA-*114*-like~* was performed using MEGA (version 6.05). The alignment used for the tree calculation and various amino acid sequences of OXA enzymes were performed with Clustal X (version 1.83). To determine whether different subtypes of *bla~OXA-*114*~* relate to different antibacterial spectra, antibacterial spectra were compared among these subtypes.

PCR
---

Total DNA was prepared and used as a template for PCR reactions. PCR screening for integrase (*intI1*, *intI2*, and *intI3*) genes was performed as described previously ([@B40]). The primers used in this study are shown in Supplementary Table [S1](#SM1){ref-type="supplementary-material"} ([@B39]; [@B25]; [@B12]; [@B24]).

The primers designed for various regions were Pf: GCATCCAAGCAGCAAG and Pr: AAGCAGACTTGACCTGA. PCR was performed using the Pyrobest DNA Polymerase according to the manufacturer's instructions (Takara). PCR products were resolved on 1.0% agarose gels, stained with ethidium bromide, and photographed with UV illumination. The PCR products were then sequenced after purifying the DNA by using the Gel Extraction Kit according to the manufacturer's directions (Axygen). The products were sequenced by Major Biological Medicine Technology Co Ltd in Shanghai.

Nucleotide Sequence Accession Numbers
-------------------------------------

The nucleotide sequences of the various regions in the integrons reported in this study were submitted to the NCBI^[2](#fn02){ref-type="fn"}^ and assigned the accession numbers KT454532, KT719385, KT719386, and KT719387 (**Figure [1](#F1){ref-type="fig"}**).

![**Schematic representation of the class 1 integron gene cassettes in *Achromobacter* spp. isolates**.](fmicb-07-00621-g001){#F1}

Results
=======

Clinical Characteristics
------------------------

These infections first occurred in 2008, and 2, 3, 5, 1, and 3 infections happened per year from 2008 to 2012, respectively. Patient characteristics are summarized in **Table [2](#T2){ref-type="table"}** and Supplementary Table [S2](#SM2){ref-type="supplementary-material"}. In total, 14 males and 1 female were included in this study. The mean age was 88.8 ± 5.4 years. All the patients had more than 3 diseases, and 10 of them had 3 or more catheters. The primary underlying diseases were coronary heart disease (CHD) and chronic pulmonary disease. Eleven patients received proton pump inhibitors (PPI), three patients received corticosteroids and two received chemotherapy. Almost all these patients were treated with various antimicrobial therapies within the previous 14 days. Chest imaging of all patients showed patchy exudation. Pleural effusion was found in 33.3% (5/15) of cases, and one case showed consolidation. The mean APACHE II, SOFA and CPIS scores were 23.4 ± 7.7, 7.4 ± 2.7, and 7.6 ± 1.64, respectively. Twelve patients were given a different antibiotic regimen after the antimicrobial susceptibility test. Nine patients were treated by mechanical ventilation. Three patients had chronic infections lasting more than 1 year. Of those with infections, 10 were alive, and 5 (33.3%) died 30 days after infection. The fatal cases were more likely to have sepsis (*n* = 3).

###### 

Detailed clinical features of HAP with *Achromobacter* spp. infection.

  No.   Sex/Age   Comorbidities                                                                                   Tube                                                 Predisposing factor                  Antibiotic use in 14 days                                      Clinical presentation                              Empiric therapy   Switched therapy   Mechanical ventilation            APACHE II   CPIS   SOFA   Compli cations   Outcome at 30 days   Chest Imaging
  ----- --------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------ -------------------------------------------------------------- -------------------------------------------------- ----------------- ------------------ --------------------------------- ----------- ------ ------ ---------------- -------------------- ------------------------------------------
  1     M/88      CHD; Chronic bronchitis; Hypertension; Malignancy                                               CVC                                                  PPI; Corticosteroids; Chemotherapy   TZP; Voriconazale; ONZ; IPM; Ceftriaxonze;                     Fever(Tmax38.4°C); Cough; Purulent Sputum          LEV               MEM                Non                               17          9      6      RF               Survived             Exudation(R); consolidation (L)
  2     M/89      COPD;OPT; Hypertension; Arrhythmia;                                                             CVC; Ureter; Stomach tube; Tracheostomy cannula      PPI                                  MIN;TZP;IPM                                                    Fever(Tmax38.5°C) Purulent Sputum                  SCF               MEM                Invasive                          25          11     11     RF               Survived             Bilateral exudation;
  3     M/97      Cerebrovascular disease; Hypertension; CHD;Chronic bronchitis; Post operation;                  Stomach tube; CVC; Tracheostomy cannula              Non                                  Non                                                            Purulent Sputum                                    TZP               TZP                Non                               15          6      5      Non              Survived             Bilateral exudation; Pleural effusion(L)
  4     M/75      ILD;CHD; Diabetes; CRF;Chronic bronchitis; Hypertension; Cerebrovascular disease; Arrhythmia;   CVC; Ureter; Stomach tube; Tracheostomy cannula      PPI                                  TZP, SXT, MXF, Linezolid; Voriconazole                         Fever(Tmax38.0°C); Purulent Sputum                 SCF               MEM                Non                               28          8      9      RF               Survived             Exudation(R)
  5     M/88      CHD; CRF; Diabetes Hypertension; Arrhythmia;                                                    CVC; Ureter; Stomach tube; Nasotracheal intubation   PPI                                  MEM; CAZ; MNZ; Caspofungin                                     Fever(Tmax38.0°C); Chill; Cough; Purulent Sputum   LEV               TZP+MEM            Non                               32          10     7      Sepsis           Died                 Bilateral exudation;
  6     M/85      CHD; Diabetes; Chronic bronchitis; Hypertension; Cerebrovascular disease;                       Stomach tube                                         Non                                  Cefditoren pivoxil                                             Purulent Sputum                                    MXF               MEM                Non                               13          5      4      Hyoxemia         Survived             Exudation(L)
  7     M/95      ILD; CHD; Hypertension; Arrhythmia; Diabetes; Cerebrovascular disease;                          CVC; Stomach tube                                    PPI                                  Non                                                            Dyspnea; Cyanosis; Cough; Purulent Sputum          FMOX              MXF                Non                               13          6      9      RF               Survived             Bilateral exudation
  8     M/87      CHD; Hypertension; Arrhythmia                                                                   CVC; Ureter; Stomach tube; Tracheostomy cannula      PPI; Corticosteroids                 MEM;MIN;SXT; FMOX;ONZ                                          Fever(Tmax38.0°C); Chill; Purulent Sputum          IPM               CAZ+TZP            Invasive                          27          6      6      RF               Survived             Bilateral exudation; Pleural effusion(L)
  9     M/93      Chronic bronchitis CHD; Diabetes Cerebrovascular disease                                        CVC; Ureter; Stomach tube; Tracheostomy cannula      Non                                  SCF;IPM; TZP; Linezolid; CIP; ONZ; Voriconazole; Caspofungin   Purulent Sputum                                    MXF               MEM+CAZ            Non-Invasive switch to Invasive   17          8      7      Sepsis shock     Died                 Bilateral exudation; Bilateral effusion
  10    M/93      COPD;CHD; CRF; Diabetes Hypertension; Cerebrovascular disease;                                  CVC; Ureter; Stomach tube; Tracheostomy cannula      PPI                                  MXF; Linezolid; Voriconazole                                   Fever(Tmax38.5°C); Chill; Purulent Sputum          IPM               CAZ+TZP            Invasive                          35          8      12     Sepsis           Died                 Bilateral exudation
  11    F/82      Chronic bronchitis;CHD; Diabetes; Cerebrovascular disease                                       CVC; Ureter; Stomach tube; Tracheostomy cannula      Non                                  LEV;SCF;MEM; Caspofungin                                       Fever(Tmax38.2°C); Purulent Sputum                 IPM               TZP+MIN            Invasive                          18          7      7      ARDS             Died                 Bilateral exudation; Bilateral effusion
  12    M/89      CHD; ILD; Chronic bronchitis; Malignancy; Cerebrovascular disease                               CVC; Stomach tube                                    PPI; Chemotherapy                    Etimicin;                                                      Purulent Sputum                                    MEM               MEM                Non-Invasive                      36          8      10     MOF              Died                 Exudation(R); Pleural effusion(R)
  13    M/92      CHD;OPT; Chronic bronchitis; Hypertension; Cerebrovascular disease                              Stomach tube                                         PPI                                  MEM;TZP;MIN; Caspofungin                                       Fever(Tmax37.8°C); Purulent Sputum                 IPM               IPM                Invasive                          21          6      4      Non              Survived             Exudation(R)
  14    M/89      COPD;ILD; CHF Cerebrovascular disease                                                           CVC; Stomach tube; Tracheostomy cannula              PPI                                  FMOX                                                           Purulent Sputum                                    SCF               IPM+MIN            Non-Invasive switch to invasive   26          8      9      RF               Survived             Bilateral exudation
  15    M/90      COPD;CHD; CRF; Diabetes Hypertension; Arrhythmia; Cerebrovascular disease;                      CVC; Ureter; Stomach tube; Tracheostomy cannula      PPI; Corticosteroids                 MXF; Linezolid, Voriconazole                                   Purulent Sputum                                    IPM               TZP                Non-Invasive                      28          8      7      RF               Survived             Bilateral exudation

CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; OPT, obsolete pulmonary tuberculosis; ILD, interstitial lung disease; CRF, chronic renal failure; CHF, congestive heart failure; RF, respiratory failure; ARDS, acute respiratory distress syndrome; MOF, multiple organ failure; CVC, central venous catheter; PPI, proton-pump inhibitor; TZP, piperacillin/tazobactam; ONZ, ornidazole; IPM, imipenem; MNZ, metronidazole; MEM, meropenem; SXT, trimethoprim/sulfamethoxazole; MXF, moxifloxacin; CAZ, ceftazidime; MNZ, metronidazole; MIN, minocycline; FMOX, flomoxef; SCF: cefoperazone/sulbactam; CIP, ciprofloxacin; LEV, levofloxacin; FEP, cefepime, R, right, L, left.

Diversity of *bla~OXA-*114*-like~*
----------------------------------

All *Achromobacter* spp. strains had positive results for the amplification of *bla~OXA-*114*-like~* (**Figure [2](#F2){ref-type="fig"}**). To further study the sequence diversity of *bla~OXA-*114*-like~* in *Achromobacter* spp., amino acid sequence comparison of the *bla~OXA-*114*-like~* gene was conducted and an evolutionary tree were constructed (**Figure [3](#F3){ref-type="fig"}**). The most frequent type was *bla~OXA-*114*q~*, which accounted for 53.3% (8/15) of isolates. Other genes included *bla~OXA-*114*r~* (three cases), *bla~OXA-*114*h~* (three cases) and *bla~OXA-*114*t~* (one case). There were amino acid differences among all of the isolates.

![**Amino acid sequence differences in the OXA enzymes described in this study**.](fmicb-07-00621-g002){#F2}

![**Dendrogram analysis of OXA enzymes in *Achromobacter* spp. isolates**. The tree was inferred for various *bla~OXA-*114*~* types, *bla~OXA-*243*~*, and *bla~OXA-*253*~* using the neighbor-joining method.](fmicb-07-00621-g003){#F3}

MLST and BF
-----------

Based on MLST, four cases belonged to ST5, and these cases were distributed in two separate buildings of the hospital. Six new STs were detected (ST306, 307, 311, 312, 313, 314). Five cases belonged to ST306, and 2 belonged to ST313 (**Figure [4](#F4){ref-type="fig"}**). Phylogenetic analysis of housekeeping genes showed that there was a less obvious relationship between ST5 and ST314 (**Figure [5](#F5){ref-type="fig"}**), which were found in cases from the general medicine department in a different building from where the other STs were isolated. Additionally, all STs available in the database were analyzed via eBURST. The results show that ST313 belongs to the ST1 CC (clone complex), and HAP caused by this organism may occur sporadically (**Figure [6](#F6){ref-type="fig"}**).

![**The distribution of the 15 patients by admission department and year. ![](fmicb-07-00621-i001.jpg): ST311 ![](fmicb-07-00621-i002.jpg):ST307 ![](fmicb-07-00621-i003.jpg):ST312 ![](fmicb-07-00621-i004.jpg):ST5 ![](fmicb-07-00621-i005.jpg):ST314 ![](fmicb-07-00621-i006.jpg):ST313 ![](fmicb-07-00621-i007.jpg):ST313 ![](fmicb-07-00621-i008.jpg):ST306.** CCU, cardiac intensive care unit; RICU, respiratory intensive care unit. General Medicine (the blue underline) is in another building. The same sequence type is shown in the same color square. The square represents male gender. The star represents female gender.](fmicb-07-00621-g004){#F4}

![**Neighbor-joining dendrogram of concatenated sequences of seven housekeeping genes from the MLST database**.](fmicb-07-00621-g005){#F5}

![**eBRUST analysis of all STs of *Achromobacter***. Circles represent different STs; blue represents a primary founder, yellow represents a subgroup founder, red denotes STs found in the present study dataset only.](fmicb-07-00621-g006){#F6}

All strains were able to produce a biofilm on 96-well plates (**Table [1](#T1){ref-type="table"}**). Nearly half of the strains were moderate biofilm producers, four strains were strong producers, and five strains were weak producers.

Antibiotic Resistance and Integron Variable Region
--------------------------------------------------

All strains were resistant to aminoglycosides, aztreonam, nitrofurantoin, and third- and fourth-generation cephalosporins (except ceftazidime and cefoperazone). Approximately half of these strains were resistant to ciprofloxacin, tetracycline and imipenem, but the sensitivity to piperacillin/tazobactam and meropenem was close to 70%.

All the *bla~OXA-*114*-like~* type strains showed high resistance to cefepime, cefotaxime and ceftriaxone and high sensitivity to piperacillin and piperacillin/tazobactam. It is interesting that both *bla~OXA-*114*t~* and *bla~OXA-*114*r~* strains are resistant to ciprofloxacin and show higher resistance to carbapenems than other subtypes (**Table [3](#T3){ref-type="table"}**, **Figure [7](#F7){ref-type="fig"}**). However, due to the small sample, a large sample analysis should be conducted to further examine this finding.

###### 

The antibacterial spectrum of *bla~OXA-*114*-like~* strain.

                      Total   CAZ   FEP   CTX   CRO   CPZ   LEV   CIP   IPM   MEM   PIP   TZP                                           
  ------------------- ------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- --- --- --- --- --- --- --- --- --- --- ---
  *bla~OXA-*114q*~*   8       6     2     0     8     0     8     0     8     6     2     5     3   2   6   4   4   7   1   7   1   7   1
  *bla~OXA-*114h*~*   3       2     1     0     3     0     3     0     3     2     1     2     1   2   1   3   0   3   0   2   1   2   1
  *bla~OXA-*114r*~*   3       2     1     0     3     0     3     0     3     2     1     2     1   0   3   1   2   1   2   3   0   3   0
  *bla~OXA-*114t*~*   1       1     0     0     1     0     1     0     1     1     0     1     0   0   1   0   1   0   1   1   0   1   0

![**The antibacterial spectrum of *bla~OXA-*114*-like~* -containing strains.** 1: *bla~OXA-*114q*~*, 2: *bla~OXA-*114q*~*, 3: *bla~OXA-*114q*,~* 4: *bla~OXA-*114q*~;* CAZ, ceftazidime; FEP, cefepime; CTX, cefotaxime; CRO, ceftriaxone; CPZ, cefoperazone; LEV, levofloxacin; CIP, ciprofloxacin; IPM, imipenem; MEM, meropenem; PIP, piperacillin; TZP, piperacillin/tazobactam.](fmicb-07-00621-g007){#F7}

We examined three types of integrons *(intI*, *intII*, *intIII)*, and all the strains had *intI*, but neither *intII* nor *intIII* were found. In the variable region in *intI*, *aadB* + *aadA2* were detected in 10 strains, *aadB* was inserted in two strains, *dfrA17*+ *aacA4* in one isolate, and *bla~PSE-1~*+*aac(6′)-II* + *aadB* in one isolate (Supplementary Figure [S1](#SM3){ref-type="supplementary-material"}).

Discussion
==========

*Achromobacter* spp. have been frequently detected by the cystic pulmonary fibrosis (CF) center in recent years ([@B16]; [@B23]; [@B3]; [@B18]). A study showed that colonization mostly occurred in elderly patients who had more pronounced lung damage and poorer lung function ([@B8]). Chronic pulmonary disease and respiratory tract infections often occur in elderly patients. In our study, elderly patients had more than three diseases, particularly CHD, chronic pulmonary disease and cerebrovascular disease. Additionally, 10 had 3 or more indwelling catheters. These catheters may contribute to the higher APACHE II and SOFA scores. The mortality rate was 33.3% (5/15), which is higher than that in other studies ([@B15]; [@B1]). Piperacillin/tazobactam and meropenem showed a strong ability to treat the infection, consistent with the *in vitro* susceptibility tests. In our study, nine patients (60%) received mechanical ventilation. This organism can colonize humidifiers, which is an issue that needs to be addressed when a patient receives mechanical ventilation ([@B33]).

More than 300 types of *Achromobacter* spp. have been recorded in the MLST database. ST5 was first cultured from a CF patient in USA. In our hospital, four cases were infected by this type from 2009 to 2012 in two buildings. These patients did not appear to be clustered in space or time. Moreover, the MIC of carbapenems for ST5 was lower. From 2008 to 2010, ST306 was detected in the Respiration and CCU. Interestingly, the same ST showed various antibiotic-resistance spectra, indicating different resistance mechanisms. The other STs (ST307, ST311, ST312, ST313, and ST314) did not appear to be clustered in space or time. Additionally, the location and timing were not consistent with the six non-clustered cases. However, no strain was detected from doctors' hands or from medical equipment. The source of their infection could not be determined. Two strains (ST313) showed higher MIC for cephalosporins, quinolones and carbapenems, which should be considered in clinical practice.

It has been proposed that *bla~OXA-*114*-like~* is an inherent gene for *Achromobacter xylosoxidans* ([@B37]). Additionally, the diversity of *bla~OXA-*114*-like~* has been reported ([@B2]). *Bla~OXA-*114*q~*, *bla~OXA-*114*r~*, *bla~OXA-*114*h~* and *bla~OXA-*114*t~* were also detected in our study, which confirmed the diversity of this gene. We have listed the similarities and differences in amino acids among these genes in our isolates. Further studies are needed to understand the function of these differences.

In our study, the strains isolated from patients who were supported by mechanical ventilation had stronger biofilm production. Additionally, the strong biofilm producers (No. 8, 10, 11) showed higher MIC of carbapenems. These characteristics may be shared by other Gram-negative biofilm producers.

Various regions of integrons can carry various resistance genes. In Argentina, class 1 integrons and class 2 integrons were detected in an *Achromobacter* spp., including various antibiotic-resistant genes ([@B35]). In the present study, only class 1 integrons were detected, and all strains were resistant to aminoglycosides, consistent with the three types of genes (*aadB*, *aadA2* and *aacA4*) detected in the integron.

The overuse of antibiotics may be a reason for the increasing opportunistic infections with resistant microorganisms ([@B32]). *In vitro*, these isolates showed high sensitivity to trimethoprim/sulfamethoxazole, polymyxin B, meropenem and piperacillin/tazobactam. In clinical practice, due to the hepatic and renal toxicity of trimethoprim/sulfamethoxazole and polymyxin B, meropenem and piperacillin/tazobactam are frequently used in therapy. Additionally, in our study, nine patients survived after meropenem and piperacillin/tazobactam therapy. However, four isolates showed high resistance to imipenem *in vitro*. In a previous study, the *bla~VIM~* located in integron I was reported in both Asia and Europe ([@B26]; [@B28]; [@B29]). Additionally, a new type of *bla~IMP~* inserted in plasmids was detected in *A. xylosoxidans*, which could easily trigger a pandemic of carbapenem-resistant isolates ([@B40]). Unfortunately, metallo-b-lactamase (MBL) gene cassettes involved in carbapenem resistance were not detected in the integrons. Other mechanisms may account for the carbapenem resistance observed in this study. Thus, whole genome sequencing may be needed for further study.

Many studies showed that *dfrA* was frequently detected in integrons ([@B42], [@B41]). In our study, *dfrA17* was found in integron I, which was once detected in patients with urinary tract infection from another Gram-negative organism in Korea. However, the clinical specimens of our patients were sputum samples. The spread of *dfrA17* may be related to the plasmid ([@B42]). The *bla~PSE-*1*~* gene was first reported in *Achromobacter* spp. This gene can induce carbenicillin-hydrolyzing beta-lactamases aimed at carboxypenicillins, ureidopenicillins and cefsulodin. These enzymes belong to molecular class A and functional group 2c ([@B5]), which can be frequently detected in Gram-negative organisms. These results indicate that this organism may be a reservoir of horizontal genetic transfer elements for spreading antibiotic resistance ([@B7]).

This study has several limitations. First, it is a small retrospective study conducted over 5 years. Therefore, the source of infection could not be determined, and our results cannot be generalized to other populations. Second, these cases of *Achromobacter* spp. in China are not routinely reported. Third, the mechanism of resistance to carbapenems was unclear. Whole genome sequencing may be needed in further studies.
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